| ASSET | QUARTER | % RETURN |
|---|---|---|
Cytokinetics (CYTK) | Q4 2014 | 125% |
Xenon Pharmaceuticals (XENE) | Q4 2014 | 97.11% |
Frontline (FRO) | Q4 2014 | 81.89% |
SkyWest (SKYW) | Q4 2014 | 72.14% |
Applied Digital (APLD) | Q4 2014 | 65.57% |
Paycom Software (PAYC) | Q4 2014 | 62.43% |
Ocular Therapeutix (OCUL) | Q4 2014 | 56.7% |
Seaboard (SEB) | Q4 2014 | 56.63% |
Varonis Systems (VRNS) | Q4 2014 | 56.26% |
TG Therapeutics (TGTX) | Q4 2014 | 48.59% |
Merit Medical Systems (MMSI) | Q4 2014 | 46.62% |
Qorvo (QRVO) | Q4 2014 | 43.64% |
CarMax (KMX) | Q4 2014 | 43.52% |
Uranium Energy (UEC) | Q4 2014 | 43.44% |
Qualys (QLYS) | Q4 2014 | 41.6% |
Chefs Warehouse (CHEF) | Q4 2014 | 41.35% |
Amicus Therapeutics (FOLD) | Q4 2014 | 40.3% |
Molson Coors Beverage (TAP.A) | Q4 2014 | 39.39% |
HealthEquity (HQY) | Q4 2014 | 39.07% |
Alaska Air (ALK) | Q4 2014 | 38.83% |
Matson (MATX) | Q4 2014 | 38.65% |
Magnite (MGNI) | Q4 2014 | 38.18% |
Perdoceo Education (PRDO) | Q4 2014 | 37.55% |
Alkermes (ALKS) | Q4 2014 | 37.5% |
Maximus (MMS) | Q4 2014 | 37.29% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
